Post marketing prospective study of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection

Post marketing prospective study of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection - Post marketing prospective study of daclatasvir and asunaprevir

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023267

Enrollment

100

Registered

2016-07-21

Start date

2014-09-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis C virus infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with genotype 1b hepatitis C virus infection

Exclusion criteria

Exclusion criteria: 1)pregnant woman 2)decompensated cirrhosis

Design outcomes

Primary

Measure	Time frame
Sustained virological response at 12 weeks after treatment	—

Countries

Japan

Contacts

Public ContactHideyuki Tamai

Wakayama Medical University Second department of internal medicine

tamahide@wakayama-med.ac.jp073-447-2300

Outcome results